Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Colorectal Cancer: Update Bulletin #1 [December 2018]

Product Code:
596201070
Publication Date:
December 2018
Format:
PDF
Price:
£1,140

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the colorectal cancer (CRC) market. Within this update, KOLs provided their views on; Oncolytics Biotech announcing positive results from a Phase I clinical trial of pelareorep (also known as Reolysin) in patients with KRAS mutant metastatic colorectal cancer (mCRC); Array BioPharma, Merck KGaA and Pierre Fabre announcing the initiation of the Phase II ANCHOR-CRC trial for its encorafenib, binimetinib and cetuximab (ENC/BIN/CTX) triplet regimen; and Bavarian Nordic announcing that the first patient has been dosed in a clinical study evaluating CV301; the company's targeted immunotherapy candidate, and durvalumab, AstraZeneca's PD-L1 inhibitor, in combination with maintenance chemotherapy for patients with metastatic colorectal and pancreatic cancer.

Business Questions:

• How encouraging do KOLs find the early data for pelareorep, and do they have any safety concerns?
• What do KOLs recommend as potential next steps in the development of pelareorep, both in terms of the immune activation data, and providing additional safety and efficacy data?
• Where and how do KOLs believe pelareorep will be used as a treatment for KRAS mutant CRC?
• How to KOLs view the recently initiated ANCHOR-CRC trial for the ENC/BIN/CTX triple regimen in terms of its impact on the Phase III BEACON trial?
• What future development strategies do KOLs believe hold the most promise for the ENC/BIN/CTX triple regimen?
• How and when do KOLs believe the ENC/BIN/CTX triple regimen will be used in treatment-naïve patients with BRAF mutant CRC?
• For CV301, will scientific interest translate into clinical success?
• Do KOLs have any issues regarding the design of CV301’s clinical trials, and what avenues exist for future development?
• How and when do KOLs believe that CV301 will be used in the treatment of CRC?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved